未登录

S

Sebastiaan C. Goulooze

lap&p consultants bv

H指数:14

被引数:510

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Dose–Exposure–Response Analysis of Finerenone on Serum Potassium and Cardiovascular Outcomes Among Patients With Heart Failure: Insights From FINEARTS ‐ HF

富马酸非布利酮剂量-暴露-反应分析：在心衰患者血清钾和心血管结局中的应用——来自FINEARTS-HF研究的启示

DIABETES OBESITY & METABOLISM

IF5.7

2026-11-030

OAAI

Impact of Event-Related Treatment Modifications in Exposure-Response Analyses of Repeated Time-to-Event Data

事件相关治疗调整对重复时间-事件数据暴露-反应分析的影响

cpt: pharmacometrics & systems pharmacology

IF0

2026-03-120

OAAI

Causal Directed Acyclic Graphs to Mitigate Confounding Bias in Exposure-Response Analyses

因果有向无环图在暴露-反应分析中缓解混杂偏倚的应用

cpt: pharmacometrics & systems pharmacology

IF0

2026-03-020

OA

Tutorial on Causal Mediation Analysis for Pharmacometricians

药代动力学专家因果中介分析教程

CPT-Pharmacometrics & Systems Pharmacology

IF3

2026-02-160

OAAI

The Drug Titration Paradox in the Presence of Intra-Individual Variation: Can we Estimate the True Concentration-Effect Relationship?

个体内变异存在下的药物滴定悖论：我们能否估计真实的浓度-效应关系？

IF3.7

2025-03-260

OA

Tutorial on Conditional Simulations With a Tumor Size-Overall Survival Model to Support Oncology Drug Development

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2025-02-210

OAAI

Development of a Joint Tumor Size-Overall Survival Modeling and Simulation Framework Supporting Oncology Development Decision-Making

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2025-02-211

OAAI

Time-varying covariates, overadjustment bias and mediation in pharmacokinetic/pharmacodynamic modeling

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2024-07-162

OAAI

When will the Glomerular Filtration Rate in Former Preterm Neonates Catch up with Their Term Peers?

PHARMACEUTICAL RESEARCH

IF4.3

2024-03-123

OAAI

Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD

DIABETES OBESITY & METABOLISM

IF5.7

2023-11-308

OA

Advances in pharmacokinetic-pharmacodynamic modelling for pediatric drug development: extrapolations and exposure-response analyses

儿科药物开发的药代动力学-药效学模型的进展: 外推和暴露反应分析

EXPERT REVIEW OF CLINICAL PHARMACOLOGY

IF3

2023-11-290

PRE

The Effect of Ibuprofen Exposure and Patient Characteristics on the Closure of the Patent Ductus Arteriosus in Preterm Infants

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2022-05-067

OAAI

Kinetics of myelin breakdown products: A labeling study in patients with progressive multiple sclerosis

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2021-11-191

OAAI

Midazolam Infusion and Disease Severity Affect the Level of Sedation in Children: A Parametric Time-to-Event Analysis

PHARMACEUTICAL RESEARCH

IF4.3

2021-10-180

OAAI

Towards Evidence-Based Weaning: a Mechanism-Based Pharmacometric Model to Characterize Iatrogenic Withdrawal Syndrome in Critically Ill Children

IF3.7

2021-05-173

OAAI

Dosing Recommendations for Vancomycin in Children and Adolescents with Varying Levels of Obesity and Renal Dysfunction: a Population Pharmacokinetic Study in 1892 Children Aged 1-18 Years

IF3.7

2021-04-1112

OAAI

Postoperative breakthrough pain in paediatric cardiac surgery not reduced by increased morphine concentrations

PEDIATRIC RESEARCH

IF3.1

2021-02-183

PREAI

The effect of food and formulation on the population pharmacokinetics of cholesteryl ester transferase protein inhibitor DRL-17822 in healthy male volunteers

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2020-04-200

OAAI

Beyond the Randomized Clinical Trial: Innovative Data Science to Close the Pediatric Evidence Gap

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2020-01-2226

OAAI

Population pharmacokinetics of vancomycin in obesity: Finding the optimal dose for (morbidly) obese individuals

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2020-01-0738

OAAI